Cargando…

Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs

INTRODUCTION: Targeted DMARD (tDMARD) use in patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) may increase whole-body insulin sensitivity. Evidence comparing the T2DM-related clinical and economic impact of abatacept versus other tDMARDs is limited. This study compared dif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Vardhaman, Pulungan, Zulkarnain, Shah, Anne, Jones, Barton, Petrilla, Allison, Ferri, Leticia, Han, Xue, Michaud, Kaleb
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314491/ https://www.ncbi.nlm.nih.gov/pubmed/35604547 http://dx.doi.org/10.1007/s40744-022-00453-w

Ejemplares similares

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
por: Triaille, Clement, et al.
Publicado: (2021)

Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey
por: Solomon, Daniel H, et al.
Publicado: (2013)

Comorbidity is associated with higher risk of financial burden in Medicare beneficiaries with cancer but not heart disease or diabetes
por: Jones, Salene M.W., et al.
Publicado: (2019)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

Diabetes care among elderly medicare beneficiaries with Parkinson’s disease and diabetes
por: Bhattacharjee, Sandipan, et al.
Publicado: (2015)

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
por: Ozen, Gulsen, et al.
Publicado: (2019)

Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials
por: Michaud, Kaleb, et al.
Publicado: (2023)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
por: Malaviya, Anshuman P, et al.
Publicado: (2012)

Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US
por: Sandhaus, Robert, et al.
Publicado: (2020)

Racial and Ethnic Disparities in the Burden and Cost of Diabetes for US Medicare Beneficiaries
por: Glantz, Namino M., et al.
Publicado: (2019)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Trend of Hospital Readmissions, Mortality, ER Visits and Observation Room Stays in Clostridium difficile Infection Cases in Medicare Advantage Population
por: Bhattacharjee, Reshma, et al.
Publicado: (2014)

Increased Nonexudative Age-Related Macular Degeneration Diagnosis Among Medicare Beneficiaries With Rheumatoid Arthritis
por: Schnabolk, Gloriane, et al.
Publicado: (2019)

Racial Disparities in Diabetes Hospitalization of Rural Medicare Beneficiaries in 8 Southeastern States
por: Wan, Thomas T. H., et al.
Publicado: (2016)

Diabetes Prevalence and Incidence Among Medicare Beneficiaries — United States, 2001–2015
por: Andes, Linda J., et al.
Publicado: (2019)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Utilization of Medicare services by beneficiaries having partial Medicare coverage
por: McCall, Nelda
Publicado: (1983)

Effect of Medicare Advantage Payments on Dually Eligible Medicare Beneficiaries
por: Atherly, Adam, et al.
Publicado: (2005)

Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
por: Bartlett, Victoria L., et al.
Publicado: (2020)

Medication adherence behaviors of Medicare beneficiaries
por: Carr-Lopez, Sian M, et al.
Publicado: (2014)

Mental Health of Medicare Beneficiaries: 1995
por: Eppig, Franklin J., et al.
Publicado: (1997)

Participation in the Qualified Medicare Beneficiary Program
por: Neumann, Peter J., et al.
Publicado: (1995)

Trends of Breast Reconstruction in Medicare Beneficiaries
por: Vyas, Krishna S., et al.
Publicado: (2020)

Bariatric surgery outcomes in Medicare beneficiaries
por: Wirth, Keith, et al.
Publicado: (2020)

Outcomes associated with comorbid atrial fibrillation and heart failure in medicare beneficiaries with acute coronary syndrome
por: Chen, Shih-Yin, et al.
Publicado: (2014)

Medication Nonadherence Among Medicare Beneficiaries with Comorbid Chronic Conditions: Influence of Pharmacy Dispensing Channel
por: Iyengar, Reethi N., et al.
Publicado: (2016)

Prevalence of Chronic Conditions Among Medicare Part A Beneficiaries in 2008 and 2010: Are Medicare Beneficiaries Getting Sicker?
por: Erdem, Erkan
Publicado: (2014)

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
por: Choquette, Denis, et al.
Publicado: (2019)

Estimating Medicare Advantage Lock-In Provisions Impact on Vulnerable Medicare Beneficiaries
por: Laschober, Mary
Publicado: (2005)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
por: Köller, Marcus D.
Publicado: (2007)

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
por: Lutt, Joseph R
Publicado: (2009)

The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis
por: Chin, Rishika V, et al.
Publicado: (2023)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Location, Location, Location: Geographic Clustering of Lower-Extremity Amputation Among Medicare Beneficiaries With Diabetes
por: Margolis, David J., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rrrv9qg1v7ogjorckapn2d50nj